Visu Contemporary is an artist first gallery where emphasis is placed on quality and presentation. Our mission is clear:
• Feature major artists while helping to develop emerging artists, through primary and secondary market sales.
• Contribute to the art history canon by presenting provocative and inclusive exhibitions, projects, installations, collaborations and performances.
• Make each exhibition a must see while inspiring curiosity and intrigue from each visitor.
• Grow arts & culture to help create a more vibrant community.
Visu Contemporary — what’s interesting in art now.
“Art has always been the raft onto which we climb to save our sanity. I don't see a different purpose for it now." -Dorothea Tanning
About Co-owner and Co-Curator Dr. Bruce M. Halpryn
Bruce M. Halpryn’s strategic guidance has been instrumental in shaping the future of numerous arts organizations, particularly in the artistic fields of visual art, glass and dance. Halpryn is currently on the board of directors of Aperture, a non-profit publisher that leads conversations around photography worldwide. Bruce also serves as the vice-chair of the Miami City Ballet. Halpryn was the president of the board of FotoFocus, the largest photography and other lens-based art biannual in the USA, for 8 years and remains on the board after reaching his term limit as president. He has been an art collector, with a large emphasis on photography, for over 40 years and has forged deep personal relationships with many of the artists in his collection. Halpryn is a shareholder of the Cincinnati Art Museum, where he had a key role in creating and maintaining the Friends of Photography Affinity Group, and a role in numerous photography acquisitions for the museum collection, underwriting numerous photography shows in the museum. Halpryn is CEO, co-founder, and board president of Eikonoklastes Therapeutics, where he continues to contribute his expertise. A serial entrepreneur, Halpryn is the founder and leader of multiple start-up pharmaceutical companies at the forefront of early-phase new drug development and regulatory affairs.